Scisparc grants global rights for pain therapy to biotech company in agreement worth up to $6 million

Scisparc would be entitled to receive consideration valued at $3 million in polyrizon securities, as well as potential milestone fees of approximately $3 million in cash

SPRC Ratings Summary

SPRC Quant Ranking